All In Biotech

Drug Trial Radar · NCT03584516

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

155

Actual

Start

Jan 17, 2019

Primary completion

Nov 3, 2023

Study completion Nov 3, 2023

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jul 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Conditions

  • Chronic Graft-versus-host Disease

Interventions

  • ItacitinibDrug

    In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.

  • PlaceboDrug

    In Part 2, participants will receive matching placebo.

  • MethylprednisoloneDrug

    Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.

  • PrednisoneDrug

    Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: up to Day 28
  2. Part 1 Expansion: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: until at least 30 days after the last dose of study treatment (up to 1103 days)
  3. Part 2: Response Rate at Month 6Time frame: Month 6

Locations

133 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center - Out Pt.

    Tucson, Arizona

  • University of Arkansas For Medical Sciences - Winthrop P Rockefeller Cancer Institute

    Little Rock, Arkansas

  • City of Hope National Medical Center

    Duarte, California

  • University of California San Diego Medical Center, Moores Cancer Center

    La Jolla, California

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Augusta University - Medical College of Georgia

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Illinois Cancer Specialists

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Advocate Lutheran General Hospital - Oncology Specislists Sc

    Park Ridge, Illinois

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • University of Kansas Hospital Authority

    Westwood, Kansas

  • Tulane University

    New Orleans, Louisiana

  • University of Maryland - Greenebaum Cancer Center

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Spectrum Health

    Grand Rapids, Michigan

  • University of Minnesota, Masonic Cancer Center

    Minneapolis, Minnesota

  • Saint Louis University Cancer Center

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • University of Rochester, James P. Wilmot Cancer Center

    Rochester, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Oncology Hematology Care, Inc

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Jefferson University Hospitals

    Philadelphia, Pennsylvania

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Tri Star Bone Marrow Transplant

    Nashville, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • St David'S South Austin Medical Center

    Austin, Texas

  • Texas Oncology - Medical City Dallas

    Dallas, Texas

  • Texas Oncology - Baylor Sammons Cancer Center

    Dallas, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Ordensklinikum Linz Gmbh Elisabethinen

    Linz, Austria

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.